"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
Lactulose Solution USP,
10 g/15 mL
FOR ORAL OR RECTAL ADMINISTRATION FOR THE PREVENTION AND TREATMENT OF PORTAL-SYSTEMIC ENCEPHALOPATHY
Lactulose is a synthetic disaccharide in solution form for oral or rectal administration. Each 15 mL of Lactulose Solution USP contains 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 0.1 g or less of fructose). It also contains D&C Yellow No. 10, FD & C Yellow No. 6 and Purified Water.
Lactulose is a colonic acidifier for treatment and prevention of portal-systemic encephalopathy.
The chemical name for lactulose is 4-O-β-D-galactopyranosyl-D-fructofuranose. It has the following structural formula:
The molecular weight is 342.30. It is freely soluble in water.
What are the possible side effects of lactulose (Enulose, Generlac, Kristalose)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using lactulose and call your doctor at once if you have severe or ongoing diarrhea.
Less serious side effects may include:
- bloating, gas;
- stomach pain;
- diarrhea; or
- nausea, vomiting.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA...
Last reviewed on RxList: 7/16/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Lactulose Solution Information
Report Problems to the Food and Drug Administration
Find out what women really need.